AKT1 and neoplasm: The dysregulation of cell signaling pathways, notably the PI3K/AKT/mTOR (PAM) pathway, significantly contributes to tumor cell proliferation and therapy resistance across a range of malignancies, encompassing breast cancer as well [3].